The incorporation of biological information in large population surveys has expanded demographic analysis to clarify the meaning of observed trends and differences in population health and mortality. Levels of measured biological risk in the population were reduced in recent years largely because of the expanded use of prescription drugs. The increased use of antihypertensives and, to a lesser extent, lipid-lowering drugs was a likely cause of signifi cant mortality reduction. Blacks and persons with lower educational attainment experience higher levels of biological risk factors, more diseases, and more frailty; these differences are the sources of higher mortality for these groups. Hispanics are less likely to have a higher prevalence of risk factors and diseases than the non-Hispanic population, providing further understanding of the "Hispanic paradox." Almost every examined indicator of biological risk, disease, and frailty is related to higher mortality, indicating how incorporation of this information provides a fuller understanding of the morbidity process.
emographers interested in health have in recent years developed new approaches to research based on more biologically informed models. The incorporation of more biological and performance measurements has allowed for the integration of additional information into models of health outcomes investigated by demographic researchers and has furthered the understanding of trends and differences in population health as well as the factors that affect individual life spans, particularly in the older population.
The word biodemography describes a number of analytic approaches, all of which include the idea that biology can inform demographic analysis (Carey and Judge 2001; Vasunilashorn and Crimmins 2008; Vaupel 2004) . In this analysis, we will focus on demonstrating that including information on biological factors in the analysis of large population surveys helps us better understand observed trends and differences in health in the older population. Three specifi c questions will be addressed for the United States: (1) What can we conclude about trends in population health from recent changes in biological risk factors?;
(2) what can we learn about differences in population health by socioeconomic status (SES) as well as race and ethnicity through examination of indicators of biological risk and frailty?; and (3) which biological risk factors, diseases, and frailty indicators predict mortality at different ages? Our answers to these questions will be derived using currently existing data from the U.S. National Health and Nutrition Examination Surveys (NHANES) .
We should note that the potential of this fi eld is only beginning to be realized as biomarker collection in recent years has been undertaken in multiple population surveys in many countries. The coming years will provide indicators of many more biomarkers and signifi cantly more data on the change within individuals in biological risk factors with age, allowing for the building of better models linking lifetime risk and lifetime health events. D *Eileen Crimmins, Jung Ki Kim, and Sarinnapha Vasunilashorn, Andrus Gerontology Center, University of Southern California. Direct correspondence to Eileen M. Crimmins, Andrus Gerontology Center, University of Southern California, Los Angeles, CA 90089-0191; e-mail: crimmin@usc.edu. Support for this research was provided by NIH Grants P30 AG017265 and T32 AG0037
BACKGROUND Theoretical Incorporation of Biological Information
A large body of biological, clinical, and epidemiological research points to the importance of identifi ed risk factors as early indicators of physiological change and as important determinants of disease, disability, and death. In the past decade, a number of papers have indicated the potential for biomarkers to clarify the physiological mechanisms by which the usual social, economic, and demographic variables "get under the skin" to affect health Seeman 2001, 2004; Goldman et al. 2009; Lindau et al. 2003; Seeman and Crimmins 2001; Turra et al. 2005; Weir 2007 ). In addition, biological measurement has provided objective, quantifi ed measures of physiological states representing the functioning of a number of organ systems and physiological processes, which helps us more effectively model the process of health change leading to mortality ( Goldman et al. 2009; Turra et al. 2005) .
Demographic analysis of health was once limited to the outcome of mortality. The advent of sample surveys almost 50 years ago expanded analysis to the study of additional health indicators. Initially, this meant expanding to self-reports of functioning problems, diseases, and overall health. Much of the demographic work incorporating information on morbidity and health has focused on indicators of disability, which is only one dimension of health-and one that may not be the most theoretically relevant in trying to determine how health differs across populations or over time (Freedman et al. 2004; Manton and Gu 2001) . Inclusion of extensive markers of disease processes and impairments into demographic models of mortality has extended our understanding of health change and mortality (Mitnitski et al. 2002) . With the measure of biomarkers and cognitive and physical performance, researchers have been further able to expand the study of health outcomes to include risk factors that occur prior to clinically diagnosed disease and disability, and to investigate indicators of major functioning loss or loss of organ function that occurs with severe physiological deterioration that may follow physiologic dysregulation and disease (Goldman et al. 2009 ).
Useful conceptualizations of the process of health change in populations have been provided by the extensive body of work produced by groups working under the auspices of the World Health Organization and the Institute of Medicine in the United States, as well as by individual researchers (see Verbrugge and Jette 1994) . Building on this work, we believe that incorporating biologically informed data allows us to better understand what might be called the "morbidity process." In populations, this process begins with physiological changes characterized by the onset of risk factors indicating physiological dysregulation, then proceeds with the onset of disease and functioning loss, and fi nally enters a frailty state characterized by a loss of organ reserve and severe physiological deterioration Fried et al. 2001; Morley, Perry, and Miller 2002) . All of these are indicators of the innate morbidity process or the process of health change that can lead to death ( Figure  1 ). With more biologically informed data, we are better able to capture this process for populations and for individuals. This dimensioning of health contrasts somewhat with the disablement process, which is infl uenced by the interaction of physical ability and environmental challenge, while the focus of the morbidity process is health change intrinsic to a person (Verbrugge and Jette 1994) .
Indicators of Biological Risk
In the last few years, biomarkers have been added to self-reports of health in a number of national and regional studies in the United States (Lindau and McDade 2007; Weinstein, Vaupel, and Wachter 2008; Weir 2007 The rapid increase in the number of studies collecting biomarkers has resulted from the development and incorporation of methods for fi eld collection of information using interviewers who are not medically trained. These include the collection of blood using dried blood spots, integrated methods for collecting and assaying blood, and collection of blood assays using small handheld meters. These methods greatly reduce the diffi culty in storage and handling of samples from traditional laboratory methods of blood collection (Lindau and McDade 2007; McDade, Williams, and Snodgrass 2007) . The range of biomarkers available from these studies varies considerably depending on the types of specimens collected and who does the collection. The two with the greatest breadth of coverage are ELSA, in which collection was done by nurses, and SEBAS, in which collection was done in a hospital setting.
Increasingly, cognitive and physical functioning are also being routinely measured in surveys. Portable meters are used to measure grip strength and lung functioning, and performance of tasks that require balance, mobility, and stamina is assessed.
There are hundreds of biomarkers related to increased risk and providing evidence of the existence of health problems. We will discuss only a small number that are measured relatively routinely in large population studies and that are related to highly prevalent health outcomes in the older population. This is an abbreviated discussion of fuller presentations on biomarkers in general ) and the links between biomarkers and mortality (Crimmins and Vasunilashorn forthcoming) .
Many large population studies have collected information on biomarkers that indicate poor functioning of the cardiovascular system and metabolic processing, as well as high levels of infl ammatory response. High systolic and diastolic blood pressure (SBP and DBP, respectively), the two most commonly measured indicators of cardiovascular risk, have been associated with cardiovascular diseases as well as mortality (Izzo, Levy, and Black 2000) . Low DBP has also been identifi ed as a risk factor for mortality (Turra et al. 2005) . Pulse rate, another indicator of cardiovascular functioning, has also been associated with increased risk of coronary heart disease (CHD), as well as cardiovascular, noncardiovascular, and all-cause mortality (Gillum, Makuc, and Feldman 1991) .
Several indicators of metabolic processes have also been related to cardiovascular outcomes as well as diabetes and other conditions, including loss of mental and physical functioning. Total cholesterol has been shown to have a direct relationship with CHD and Death all-cause mortality (Manolio et al. 1992 ); however, low total cholesterol has also been identifi ed as having risks at older ages (Weverling-Rijnsburger et al. 2003) . Low levels of high-density lipoprotein (HDL) cholesterol have also been associated with an increased risk for heart disease (Barter and Rye 1996; Gordon et al. 1989) . Individuals with a high body mass index (BMI), another metabolic marker, are at greater risk for hypertension, adult-onset diabetes mellitus, heart disease, stroke, various types of cancer, atherosclerosis, osteoarthritis, and disability (Blaum et al. 2003; Dey et al. 2002; Must et al. 1999; Seidel and Visscher 2000) . The link between high BMI and mortality, once widely accepted, now appears to be less clear except at very high levels of BMI. While studies of middle aged and older populations now regularly fi nd no relationship between being overweight and mortality, and elevated mortality among those below normal weights, a review of cohort studies indicates that many studies may underestimate the risks linked to long-term higher weight for a number of reasons (Allison et al. 1997; Zamboni et al. 2005) . Glycated hemoglobin is an indicator of glucose regulation over recent months and is fairly regularly collected in population surveys from nonfasting populations. This measure can be used as an indicator of a prediabetic condition, initial diabetes screening, and diabetic control (Rohlfi ng et al. 2000) . High levels of glycated hemoglobin have been related to subsequent cardiovascular disease and mortality (Khaw et al. 2004 ). Homocysteine, a marker related to nutrition, is an amino acid that plays a role in lipid metabolism and has been associated with cardiovascular and cerebrovascular disease (Verhoef et al. 1996) .
Finally, markers of infl ammation include potential indicators of both risks for disease and the effects of disease. C-reactive protein (CRP), an acute phase protein refl ecting a general systemic infl ammatory response, increases as part of the immune response to infection and tissue damage or injury. CRP may also be elevated due to the presence of chronic conditions like diabetes, asthma, rheumatoid arthritis, and heart disease (Danesh et al. 1998; Rifai and Ridker 2001) . Chronically high levels of CRP have been shown to be related to the development of cardiovascular disease, cardiac events (including heart attack and stroke), physical decline, cognitive decline, and mortality Harris et al. 1999; Reuben et al. 2002; Ridker et al. 2000) . Elevated fi brinogen, a protein that is related to blood clotting, has been strongly predictive of both mortality and the onset of cardiovascular disease (Patel et al. 1994; Ridker et al. 1997) . Low albumin, a protein important in the maintenance of oncotic pressure in the blood and a potential indicator of both nutrition and infl ammation, has been related to heart attack, stroke, function loss, cognitive impairment, and death among older persons (Cattin et al. 1997; Goldman et al. 2009; Kuller et al. 1991) .
Indicators of Frailty
The concept of frailty developed by geriatricians emphasizes the decline in physiological systems represented by increasing loss of reserves and resilience, lack of energy, and inability to function (Cigolle et al. 2009; Fried et al. 2001; Lunney et al. 2003; Lunney, Lynn, and Hogan 2002; Mitnitski et al. 2002; Morley et al. 2002; Yashin and Iachine 1997) . Fried and colleagues (2004) have defi ned frailty as an aggregate expression of risk resulting from age-or disease-associated physiologic accumulation of sub threshold decrements affecting multiple physiologic systems that can be detected by clinical, behavioral, functional, and biological markers. Cigolle et al. (2009) have provided a good summary of multiple approaches to measuring frailty. Indicators of frailty in previous research have included self-reports of functioning abilities and health defi cits, measures of cognitive impairment, depression, slow gait speed, weight loss, fatigue, weakness, exhaustion, and low energy expenditure (Al Snih et al. 2009; Bandeen-Roche et al. 2006; Fried et al. 2004; Kulminski et al. 2008b; Mitnitski et al. 2002; Rothman, Leo-Summers, and Gill 2008) .
We develop a set of frailty indicators for this analysis from existing data that include indicators of reduced organ reserve, assessed poor cognitive functioning, and measured poor physical performance, derived from tests of strength, balance, and dexterity in functioning.
Our measures of organ reserve include indicators of reduced kidney, immune, and lung functioning. Here, we build somewhat on the work of Goldman et al. (2009) , who identifi ed related markers of kidney and immune functioning as important predictors of mortality among older Taiwanese. Cystatin C is an indicator of kidney function, and high levels are related to mortality, heart disease, and stroke among older persons Shlipak, Sarnak, and Katz 2005) . Levels of cytomegalovirus (CMV) at older ages serve as an indicator of functioning of the immune system (Koch et al. 2006) . CMV is a herpes virus that infects most people relatively early in life, and the increase in viral level at older ages is thought to represent an inability of the immune system to control the virus. High antibody levels to CMV have been associated with cardiovascular disease, frailty, cognitive decline, and mortality (Aiello et al. 2006; Blum, Peleg, and Weinberg 2003; Pawelec et al. 2009; Schmaltz et al. 2005) . We also include poor lung function among our frailty indicators because lung function has been associated with all-cause and cardiovascular mortality (Mannino et al. 2003) . It is measured by forced expiratory volume relative to forced vital capacity.
Cognitive functioning is assessed using tests of both immediate and delayed recall of details of a story, recall of words, and orientation. Impaired cognitive function has been linked to shorter life expectancy (Lievre, Alley, and Crimmins 2008) . Assessments of physical functioning ability include performance on a timed walk, chair stands, ability to lock/unlock with a key, and a timed-tandem stand (Rothman et al. 2008) . Physical functioning ability has been associated with mortality (Guralnik et al. 1994) .
In this overview paper indicating how biodemographic approaches can help understand demographic questions, we examine change over time and differences across social and geographic groups in dimensions of the "morbidity process." We also examine links between mortality and health dimensions of the process and then link the changes in biomarkers to their potential effect on mortality change. Data used to address the three questions raised in the introduction come from the U.S. NHANES surveys. Details on operational defi nitions of variables are included in Appendix Table A1 ; details on data sources and sample size are in a supplement on Demography's Web site (http://www. populationassociation .org/publications/demography).
RESULTS

How Have Individual Biological Risk Factors Changed in Recent Years?
Our analysis of change over time in biological risk builds on and updates work done about fi ve years ago examining change between 1988-1994 and 1999-2000 using data from NHANES for respondents aged 65 and older (Crimmins et al. 2005; Kim et al. 2006 ). Here, we extend the analysis using data from 2003 through . From 1988 in biomarkers were mixed in the population; some indicators of biological risk changed toward better health, and some changed toward worse health. Measured levels of high cholesterol were reduced, and measured hypertension became worse. The reduction in high cholesterol was linked to increasing diagnosis of raised cholesterol and use of lipid-lowering medication. The increase in hypertension was linked to more undiagnosed hypertension and more diagnosed and treated hypertension that was not under control even with prescribed drugs.
There were also increases in weight and in the prevalence of high CRP in the population. These changes were at least partly linked because CRP is higher among the obese. During this period, there was a marked reduction in homocysteine resulting from the addition of folate to cereals and fl our.
Changes between 1999-2000 and 2003-2006 have consolidated some previously observed changes and improved the population level of biological risk in some markers (Table 1) . For instance, the prevalence of high cholesterol has continued to drop to extra ordinarily low levels. Only 10.7% of the older population have measured high lowdensity lipoprotein (LDL) cholesterol, while 16.3% have measured high total cholesterol, and 20.6% have adverse levels, or low, measured HDL cholesterol. Reduction in the level of measured high cholesterol has been remarkable in such a short time.
Increases in obesity and high CRP, which were very signifi cant between the fi rst two periods, have not continued. In fact, the prevalence of high CRP is reduced somewhat, although the change is not statistically signifi cant (p = .06). Remarkably, given that they are related to weight, triglycerides and glycated hemoglobin stayed constant over the whole period.
The most dramatic change in these few years is in the level of high blood pressure among the older population. We noted an increase in the percentage of people with hypertension linked to an increase in the proportion with high SBP from 1988-1994 to 1999-2000, but now we note a highly signifi cant drop from 1999-2000 to 2003-2006 in both SBP and DBP. In this very short period, measured high SBP has declined from being observed in more than half the older population (52.3%) to just over a third (36%).
The changes in measured hypertension and high cholesterol are largely explained by the increased use and improved effi cacy of drugs rather than by a decrease in the likelihood of being diagnosed with either of these risk factors. 1988-1994 1999-2000 2003-2006 and 1999-2000 and 2003-2006 Systolic to 49% for men and from 45% to 56% for women. Over the same period, the proportion of users of antihypertensive medication who measured as having controlled blood pressure (not shown in the fi gure) increased from 48% to 68% for men and from 34% to 55% for women. This probably results from both an increase in the practice of prescribing drugs for people at lower levels of measured blood pressure and using more effective medications.
The changes are similar for cholesterol. While there were declines in measured high cholesterol, diagnosed cholesterol (measured high or taking medication) increased markedly among men after 1999-2000 ( Figure 3 ). These increases were paralleled by increases in drug usage. From 1999 From -2000 From to 2005 From -2006 , the proportion using drugs among those aged 65 and older increased from 24% to 37% for men and from 21% to 35% for women. Use of cholesterol-lowering drugs is likely to result in controlled cholesterol or cholesterol measured below risk level. Control among persons using drugs to treat high cholesterol increased between 1999-2000 and 2005-2006 , from 84% to 93% for men and from 76% to 88% for women (data not shown).
The use of cholesterol-lowering drugs may also be related to declines in CRP, considering that lipid-lowering drugs have been linked to lower CRP (Mora and Ridker 2006) . Among people taking cholesterol-reducing drugs in the NHANES older sample, mean CRP is 4.5 mg/L, while it is 5.5 mg/L for those not using drugs to control cholesterol. In fact, in regressions predicting CRP level, both obesity and use of cholesterol-lowering drugs are related to measured CRP but in the opposite direction. Being obese is linked to a higher level of CRP (coeffi cient = 0.149, p = .0004), while the use of cholesterol-lowering a. Men 1999-2000 2001-2002 2003-2004 2005-2006 b. Women 1999-2000 2001-2002 2003-2004 2005-2006 drugs reduces CRP by about the same level (coeffi cient = -0.110, p = .0012). Though we do not show differences by gender here, higher CRP is also linked to the use of hormone therapy (HT) among women, and the marked increase in the use of HT from NHANES III (1988) (1989) (1990) (1991) (1992) (1993) (1994) to 1999-2000 was probably another factor in the rise of CRP in that period. Some of the reduction in high CRP between 1999-2000 and 2003-2006 results from a reduction in the use of hormone therapy. Use of these drugs linked to higher CRP dropped markedly among women because of reports of adverse links between HT and cardiovascular events ). Thus, in recent years, population risk levels of a number of biomarkers have dropped signifi cantly in the older American population. None of those examined has risen since 1999-2000. Most of the changes in risk over time appear to be linked to changes in drug usage. Neither the decline in the proportion of people with hypertension nor high cholesterol occurred because fewer people had ever been diagnosed with the risk factor, which would have indicated an improvement in underlying health; rather, a growing number of people are having their levels of these risk factors controlled by drugs. Because the use of drugs for the control of cholesterol and hypertension has been shown to reduce the likelihood of strokes, heart attacks, and mortality from what they would be without the drug usage (Benetos et al. 2003; Shalev et al. 2009) , risk for downstream outcomes should have improved in the most recent period.
Are There Racial/Ethnic and Socioeconomic Differences in the Morbidity Process?
Incorporating biological risk and frailty indicators starts to provide explanations for how the social indicators "get under the skin" to produce differential health outcomes. People who live in different social circumstances have experienced lifetimes of different stresses, injuries, living and working circumstances, and medical care. There is also a large body of evidence relating individual risk factors to SES in the United States, the United Kingdom, and Asia (Albert et al. 2006; Alley et al. 2006; Crimmins et al. 2008; Dowd and Goldman 2006; Kunz-Ebrecht, Kirschbaum, and Steptoe 2004; Seeman et al. 2008) . Also, a number of analyses have shown that cumulative biological risk, or the total number of biological risk indicators in the high-risk zone, is negatively associated with both education and income (Crimmins, Kim, and Seeman 2009; Hu et al. 2007; Kubzansky, Kawachi, and Sparrow 1999; Seeman et al. 2004 Seeman et al. , 2008 . Earlier analyses of NHANES data have shown that blacks, Hispanics, and people with lower educational levels have higher overall biological risk and higher levels of some of the frailty indicators used here (Banks et al. 2006; Bravata et al. 2005; Crimmins, Hayward, and Seeman 2004; Crimmins et al. 2007; Geronimus et al. 2006; Merkin et al. 2009; Seeman et al. 2008) . Controls for SES have been shown to eliminate many of the differences in biological risk between Hispanics and non-Hispanic whites, but they do not eliminate the differences between blacks and non-Hispanic whites . Evidence of links between SES and biological risk is not always found. For instance, Dowd and Goldman (2006) and Hu et al. (2007) reported fairly weak relationships in Taiwan.
The analysis presented here examines differences between blacks, Hispanics, and others (primarily non-Hispanic whites) in three educational groups-less than 12 years (low education), 12 years (the omitted category), and more than 12 years (high education)-in individual indicators of the dimensions of the morbidity process. We use recent data for the population aged 40 and older for the indicators of biological risk and disease presence from NHANES 2003 NHANES -2006 (Table 2) . Frailty indicators are not available for persons younger than 60 or in the later NHANES surveys; thus, we examine differences in the frailty indicators for those 60 and older using data from 1988-1994, which has richer data on frailty. We also examine the links between race/ethnicity and education simultaneously (Table 2, Model 3). This serves to indicate how much of the racial/ethnic difference in health risk can be attributed to educational differences as well as to provide some disentangling of the independent effects of each of these variables. Table 2 shows odds ratios from logistic regressions of individual indicators of morbidity on race/ethnicity, and education with controls for age and gender in which each indicator of the morbidity process is defi ned dichotomously as high risk for poor outcomes or not. Blacks have a higher likelihood than the reference category of whites and others of having high-risk levels of most biological risk factors. This indicates that blacks have worse physiological dysregulation across multiple systems: cardiovascular, insulin processing, and infl ammatory. Odds ratios indicate that the likelihood of having a biomarker in the high-risk range is 1.4 to 2.7 times as high for blacks as for whites and others in the 40-and-older age range. Blacks, however, do not have higher cholesterol; in fact, they have a signifi cantly lower prevalence of high-risk total and HDL cholesterol, a fi nding that has been reported previously in the literature (Gartside, Khoury, and Glueck 1984) . In addition, there is no difference between blacks and whites in the prevalence of low DBP, low BMI, and high pulse rate. There is no change in the signifi cance of any of these differences with controls for education.
Hispanics do not differ from non-Hispanic whites and others in the likelihood of having high-risk levels of as many biological markers as blacks. The only three biological markers for which Hispanics aged 40 and older have a higher prevalence of high-risk level are HDL cholesterol, glycated hemoglobin, and CRP. Hispanics are less likely to have low BMI. With the exception of low BMI, these differences remain signifi cant with controls for education.
Differential use of drugs to control hypertension could potentially affect observed racial and ethnic differences in prevalence of hypertension and high cholesterol. However, when drug usage is included in equations, the higher levels of hypertension among blacks and high-risk HDL cholesterol among Hispanics are not eliminated or explained by differential drug usage. Blacks are most likely, and Hispanics are least likely, to use antihypertensive drugs in this sample: 44% for blacks, 31% for whites, and 21% for Hispanics. Cholesterol-lowering drug usage is most common among whites (22%); less common among blacks (18%); and least common among Hispanics (15%).
Blacks have a higher prevalence of diabetes, congestive heart failure, and stroke. Controls for education eliminate the signifi cance of the difference in stroke. They report less diagnosed (and survived) cancer and angina. Blacks do not report an excess prevalence of heart attacks, but we should note that, as with cancer, one needs to survive a heart attack to be present in the interview. These fi ndings on disease differences are similar to those reported in Hayward et al. (2000) .
Diabetes is the only disease examined here that is more likely to be reported as diagnosed among Hispanics relative to non-Hispanic whites and others. Heart attack, cancer, and bronchitis and emphysema are less prevalent among Hispanics. Similar fi ndings for cancer differences in other data sets have led us to suggest that it is possible that Hispanics diagnosed with cancer become return migrants (Crimmins, Hayward, and Seeman 2004) . Less smoking may explain less bronchitis and emphysema.
Most of the frailty indicators are more prevalent among blacks. Poor cognitive functioning, poor immune functioning, and poor physical functioning as indicated by four measures are more common among blacks 60 years of age and older. Controls for education do not eliminate the signifi cance of any of these differences. Hispanics are more likely to have poor cognitive and physical performance on three tests than non-Hispanic whites and others. Controlling for education reduces the difference in performance on the chair stand to insignifi cance.
The prevalence of high-risk levels of most biological markers is lower among those with more education. But only for glycated hemoglobin are the differences consistently signifi cantly different across the educational groups examined here. For most biomarkers, either the low-education group has a higher prevalence or the high-education group has a lower prevalence than the middle education group. The exceptions are DBP (both low and high) and low BMI; the pattern of differences in albumin is not consistent. Diabetes and the indicators of heart disease are more common among those with less education. All of the indicators of frailty are more common among those with less education except for poor performance on the tandem stand.
With controls for race/ethnicity, education remains linked to most of the biological risk factors. Persons with more education have a lower likelihood of having high levels of SBP, total cholesterol, obesity, and glycated hemoglobin. The likelihood of measuring high risk on these factors is 20% to 40% lower among people with 12 or more years of education than among those with 12 years of schooling. High pulse rate, low total and HDL cholesterol, high homocysteine, and low albumin levels are more common among those with less education. Inclusion of information on use of drugs indicates that educational differences in high blood pressure and cholesterol do not result from differential use of antihypertensives or lipid-lowering drugs. The prevalence of most diseases is also related to education. Higher education is linked to a lower prevalence of diabetes and heart attack; lower education is linked to a higher prevalence of congestive heart failure and heart attack. Persons with more education report more cancer prevalence than others. Almost all the frailty markers are linked to education such that persons with more education have less frailty.
Our analysis shows that blacks suffer a higher prevalence of adverse health conditions across the morbidity process: a higher presence of at-risk levels of biomarkers, some diseases, and more frailty. The fact that most of these differences remain with controls for education explains why analyses are often unable to "explain" the worse health of blacks by controlling for SES (Hayward et al. 2000) . In turn, the fact that differences between Hispanics and non-Hispanic whites and others are not as great in biological risk and that most diseases do not differ between these groups may help to explain the "Hispanic Paradox" of the often-observed similar levels of mortality between non-Hispanic whites and Hispanics. However, we should note that diseases are self-reports of doctor diagnosis and may not be complete for groups with less-regular health care, such as the Hispanic population.
Finally, our fi ndings depend very signifi cantly on the age group examined. We have shown in earlier work that biological risk differences in the population vary by age (Crimmins et al. 2003; and that SES differences in biological risk are reduced at the older ages through the process of selection by mortality (Crimmins, Kim, and Seeman 2009) . At each age, mortality differentially eliminates both those with higher biological risk and lower SES; this process reduces differentials at the older ages. When we repeat the analysis presented here for the sample aged 80 and older (data not shown), there are almost no signifi cant racial/ethnic or educational differences in any of the biomarkers, diseases, or frailty indicators. We believe that this elimination of socioeconomic and racial differences in biological risk and diseases at the older ages results in the observed elimination of mortality differences by race and SES at the oldest ages (Crimmins, Kim, and Seeman 2009) . We examine links between mortality and biological risk, disease, and frailty below.
Prediction of Mortality Using Indicators of the Morbidity Process
Signifi cant research has shown that individual and combined risk factors are early indicators of physiological change and predict mortality (Crimmins and Vasunilashorn forthcoming; Goldman et al. 2009; Seeman et al. 2004; Turra et al. 2005) . Here, we examine how the combination of biological risk factors, diseases, and frailty indicators predict mortality and how their inclusion affects the relationship of race/ethnicity and SES to mortality. In predicting mortality for older Taiwanese adults, colleagues (2006, 2009) have noted the importance of adding to clinical cardiovascular and metabolic markers what they term nonclinical markers, which include some indicators similar to the infl ammatory and frailty markers examined here. They and others also emphasize the importance in analyses of mortality of neuroendocrine markers and indicators of the functioning of the hypothalamic pituitary axis and sympathetic nervous system (Goldman et al. , 2009 Seeman et al. 2004) . Unfortunately, these markers are not collected in NHANES and are not a part of our analysis. The importance of disease in predicting mortality has certainly long been recognized (Kulminski et al. 2009 ). Heart disease and cancer account for most deaths (Jemal et al. 2005) , but other diseases, such as diabetes (Morgan, Currie, and Peters 2000) , are particularly important causes of early mortality. Kulminski and colleagues have shown the importance of including markers that span what we are terming the morbidity process in predicting mortality for the Framingham cohort (2008a) and the Cardiovascular Health Study (2008b).
This analysis of mortality is based on deaths in the earlier NHANES III (1988) (1989) (1990) (1991) (1992) (1993) (1994) , examined above. The data collected from 1988 through 1994 have been supplemented with mortality follow-up data from the National Death Index through the year 2000. For each person, we examine death within fi ve years from the date of interview up to 2000. Persons with death from violent causes were eliminated from the analysis.
Hazard models are used to examine the relationship between each individual indicator of biological risk, disease, frailty, and subsequent mortality (Table 3) . Models are fi rst estimated separately to see the link between each indicator and mortality (column 1) and then in hierarchical equations, including all health indicators, but introducing one set of measures at a time. Because of data availability, these equations include only the biological risk factors and diseases for the sample aged 40 and older and add the frailty markers for the sample aged 60 and older.
Links between mortality and individual measures. All of the biological risk factors are related to mortality when examined separately except high DBP (Table 3 ). Most of the markers of high risk are linked to higher mortality; obesity, however, is actually linked to lower mortality, while being underweight is linked to higher mortality. The protective effect of higher weight and negative effect of lower weight have been observed in many studies of mortality over a fi ve-year time period such as this.
The largest adverse effects on mortality come from high SBP, low DBP, low BMI, high glycated hemoglobin, high fi brinogen, and low albumin. Some of these markers, such as blood pressure and indicators of insulin processing, are fairly regularly monitored clinically in the population, while markers of infl ammation and coagulation, such as fi brinogen and albumin, are less regularly monitored.
Because most of the biomarkers are risk factors for cardiovascular disease, we also examine the links between these biomarkers and cardiovascular and noncardiovascular mortality separately (data not shown). Many of the markers are more strongly related to cardiovascular mortality than other mortality: high SBP, low DBP, high total cholesterol, high glycated hemoglobin, high CRP, and high fi brinogen. On the other hand, low BMI and low cholesterol are both more strongly related to death from other causes than from cardiovascular causes.
Each one of the diseases is signifi cantly related to higher mortality, increasing the relative likelihood of dying by 2 to 5 times (Table 3) . Having a disease seems to be generally more predictive of death than having a biological risk factor, which fi ts with our notion that disease is a progression of morbidity. All of the frailty measures are related to mortality, and the odds ratios range from 1.5 to about 4. Indicators of organ functioning are particularly strongly related to mortality. People with poor cognitive, physical, immune, kidney, and lung function are more likely to die.
Mortality and independent effects of risk factors with others controlled. The effect of all biological risk factors and all diseases together are considered sequentially in two equations: all biological risk factors, and then with diseases added. For the whole sample aged 40 and older, when all biological risk factors are included together, none of the cholesterol indicators predict mortality. This must arise from the collinearity among the risk factors. This indication of shared variance across the risk factors is anticipated as the idea that the risk factors often occur together is at the root of summary measures such as metabolic syndrome, syndrome X, and allostatic load (Seeman et al. 2010) . When diseases are included in the equation, two biological markers-high pulse rate and glycated hemoglobin-are no longer signifi cantly related to mortality, indicating that diagnosed diseases accounted for some of the variability in the biomarkers, as we would expect in this process. Having any one of the diseases, except angina, remains related to increased mortality, with each of them approximately doubling risk.
The same analysis is presented with the sample limited to those aged 60 years and older, and frailty indicators are added in a third equation. All of the frailty markers when considered alone are strongly related to mortality. Poor kidney function is linked to a fourfold higher mortality. For those aged 60 and older, when all the biomarkers are included together, fewer biological risk indicators are signifi cantly related to mortality than among the population aged 40 and older (Model 1). When the diseases and biomarkers are included together, the presence of each of the diseases, except angina, predicts higher mortality, similar to the results for the population aged 40 and older (Model 2). When the frailty indicators are added, a number of those frailty indicators are highly predictive of mortality, but cognitive function, lung function, and performance on the chair stand are no longer signifi cant (Model 3). Poor kidney function still doubles the likelihood of mortality. In this equation, most of the diseases no longer predict mortality, the exceptions being bronchitis/ emphysema and cancer (Model 3). This link between later parts of the morbidity process and mortality at older ages indicates that the measures we considered earlier in the process become superseded by their sequelae in predicting mortality.
When we limit the analysis to an even older group-those aged 75 and older-very few biomarkers, diseases, or frailty indicators predict mortality, as shown in the last panel of Table 3 . Only two biomarkers (glycated hemoglobin and low BMI), diabetes and congestive heart failure among the diseases, and kidney functioning are signifi cantly predictive of mortality. When all morbidity indicators are included together, only kidney functioning and high cholesterol predict mortality.
We should note that when race/ethnicity and education are included in these models with the indicators of the morbidity process, the demographic variables no longer are signifi cantly related to mortality among the 40-year-olds. This means that the indicators of biomarkers, disease, and frailty have picked up the variance normally explained by social factors, and thus these variables characterizing the morbidity process at least partly explain how race/ethnicity and SES "get under the skin" to produce higher mortality.
Links Between Trends in Medication and Mortality
We have noted that medication usage has increased markedly in recent years in the United States and that declines in the proportion of individuals with hypertension and uncontrolled high cholesterol could be related to recent decreases in mortality (Preis et al. 2009 ). In this section, using the NHANES III sample, we examine differences in mortality among those with high measured risk that is not controlled, those with risk controlled by drugs, and those who have never been diagnosed with hypertension or high cholesterol (Table 4) . For hypertension, we look at measured risk in SBP; for cholesterol, we examine total cholesterol. We can then link these results to changes over time in control of hypertension and cholesterol to perform an initial assessment of the importance on mortality of increasing use of medications.
We provide odds ratios from logistic regressions for the sample aged 40 years and older that indicate the relative likelihood of dying from all causes and of dying from cardio vascular disease for persons with uncontrolled hypertension or cholesterol and for persons with controlled levels of hypertension or cholesterol relative to those who have never been diagnosed. The observed relationships between mortality and the three hypertension and cholesterol states should characterize the time period of the mid-1990s. The relative likelihood that persons with uncontrolled blood pressure will die in the upcoming fi ve years is three times as high as for those who have never been diagnosed with hypertension; and those with controlled SBP have a relative likelihood of death about twice as high as those who have never been diagnosed. The increased relative risk is even higher for cardio vascular death.
In this age group, between 1999-2000 and 2005-2006 , the percentage of persons with controlled blood pressure increased from 14.6% to 20.2%, and the percentage with measured high blood pressure decreased from 29.0% to 23.2%. If the relative level of mortality for the three groups estimated from the equations in Table 4 were applicable in both time periods, and the distribution of the population across control states changed as described, the probability of dying within fi ve years for the entire population aged 40 and older would be estimated to decrease by 3.4% because of better hypertension control.
When cholesterol state is divided into those measured high, those with control, and those never diagnosed, the differences on mortality for the groups are much smaller than those for hypertension. The relative risk of mortality for those with measured high cholesterol is 28% higher than that for persons who have never been diagnosed, and there is no signifi cant difference in mortality between those with controlled cholesterol and those who have never been diagnosed with high cholesterol. This results in a much smaller estimated effect on overall mortality probability change from the increase in controlled cholesterol. In 1999-2000, the level of controlled cholesterol was 11.2%, and this increased to 18.6% by [2005] [2006] . During the same period, measured high cholesterol dropped from 23.6% to 18.8% among those aged 40 and older. Because of the relatively small effect on mortality, these changes are estimated to have reduced the probability of dying within fi ve years for that population by only 0.5%.
CONCLUSION
The inclusion of measured biological information has changed how studies of population health are conducted. Such information has furthered our understanding of the process of health change and the reasons for health differences within populations. Research that has included biomarkers has provided clarifi cation of the multiple physiological paths affected by social and economic circumstances, particularly for the older population. The true value Odds ratios are from logistic regressions on mortality for all death, and multinomial logistic regressions for cardiovascular death. All models have controls for gender. Controlled systolic blood pressure is defi ned as having low measured SBP but taking medication for blood pressure. Controlled cholesterol is defi ned as having low measured total cholesterol but taking medication for cholesterol. b Th e reference group is those who did not die. of the biodemographic approach will be realized in the coming years as many new data sets become available and some existing ones develop multiple waves with longitudinal biomarker and performance data. Multiple waves will allow the study of the onset of biological risk and frailty in a specifi c time period. It will also allow the linking of the development of biological risk and associated consequences within individuals.
These population-based studies with biomarkers tend to be broad-based social science studies designed to address trends and differences in health in a multidisciplinary framework. They provide a much richer data matrix into which the biomarkers can be embedded than some previous, more clinically oriented studies with limited lifetime social and economic data. Being able to link biomarkers and performance measures to the wealth of information characterizing lifetime social, psychological, and economic circumstances will be the payoff from adding this material to social surveys.
The biomarkers reviewed here are a small fraction of those we are likely to be examining in the future. Improved collection methods will result in national-level data sets with better markers related to social processes, such as stress. The largest change we will experience in the coming decade is the inclusion of genetic information. Many of the studies now collecting biomarkers already have signifi cant genetic information, which will increasingly provide analyses of the interactions of genetic, biological, social, economic, and demographic characteristics.
As biomarkers continue to be studied and added to surveys across countries, international comparative studies will further our understanding of the fundamental underpinnings of health and the effects of social and environmental factors. Combining a bio demographic approach with a global perspective opens the potential to more fully understand the complexities of the morbidity process and the factors infl uencing trends and differences in population health and mortality. 
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